RxDoctor Payments Data

Sabrina Taylor, DO

Family Medicine · Sioux Falls, SDNPI 1275948986

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 35.5% of the total. Reporting peaked in 2022 at $765 and has fallen 97.5% since, to $19 in 2023. Among family medicine clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,185in general payments, 2019–2025

Across 190 payments — averaging $11.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$775
  • Amgen$240
  • AstraZeneca$187
  • Biohaven Pharmaceutical Holding Company Ltd.$172
  • GSK$106
  • Astellas Pharma US Inc$74
  • plus $631 from 19 others

What the payments were for

  • Food & beverage$2,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,185 in reported general payments places this provider in the 90th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$33,373
Medicare patients
202
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$32,440
OzempicSemaglutide13$12,511
JardianceEmpagliflozin14$10,595
XareltoRivaroxaban29$9,599
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,964
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,717
Levothyroxine Sodium150$1,311
Rosuvastatin Calcium91$1,303
Gabapentin75$1,017
Atorvastatin Calcium127$941
Duloxetine Hcl26$889
Memantine Hcl ErMemantine Hcl21$827
Pantoprazole Sodium47$719
Omeprazole81$683
Amlodipine Besylate99$552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$32,44033 claims
Novo NordiskOzempic$60$12,51113 claims
Boehringer IngelheimJardiance$36$10,59514 claims
Johnson & JohnsonXarelto$52$9,59929 claims
GSKAnoro Ellipta$106$8,96419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →